SCHEMBL17987142

SCHEMBL17987142

Cc1ccccc1Cn1cnc2c(C)cccc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.69
CYP11B2 P19099 4/20 0.69
ALDH1A1 P00352 4/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
LMNA P02545 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
TNF P01375 1/20 0.51
THRB P10828 1/20 0.50
NPC1 O15118 1/20 0.45
GALR3 O60755 1/20 0.45
NR2F2 P24468 1/20 0.45
RAB9A P51151 1/20 0.45
TSHR P16473 3/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
P2RX7 Q99572 1/20 0.44
MAPK1 P28482 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20428044 0.88 CYP11B1 (0.55) CYP11B1CYP11B2ALDH1A1MEN1KMT2A
SCHEMBL229001 0.84 LMNA (0.59) CYP11B1CYP11B2ALDH1A1MEN1KMT2A
SCHEMBL10129568 0.80 CYP17A1 (0.45) CYP11B1CYP11B2ALDH1A1MEN1KMT2A
SCHEMBL5205094 0.78 MEN1 (0.44) CYP11B1CYP11B2ALDH1A1MEN1KMT2A
SCHEMBL19911313 0.78 CYP11B1 (0.41) CYP11B1CYP11B2ALDH1A1MEN1KMT2A
SCHEMBL19848066 0.77 TLR8 (0.43) CYP11B1CYP11B2ALDH1A1LMNASMN1; SMN2
SCHEMBL9570033 0.75 TDP1 (0.44) CYP11B1CYP11B2ALDH1A1MEN1KMT2A
SCHEMBL19848365 0.75 TRPM5 (0.42) CYP11B1CYP11B2ALDH1A1MEN1KMT2A
SCHEMBL9597264 0.75 TRPM5 (0.44) CYP11B1CYP11B2LMNASMN1; SMN2HTT
SCHEMBL19848357 0.74 CYP17A1 (0.64) CYP11B1CYP11B2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222011-A1 COMT Inhibiting Methods and Compositions LIEBER INSTITUTE, INC. 2016-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222011-A1 COMT Inhibiting Methods and Compositions COMT, SLC6A3, MAOA CYP11B1 35/4885CYP11B2 65/4885ALDH1A1 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.